Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Stock Popped Today

By Joe Tenebruso - Feb 19, 2021 at 8:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech gave investors 1.1 billion reasons to celebrate.

What happened

Shares of Novavax (NVAX -2.29%) rose 4.8% on Friday after the biotechnology company struck a deal to supply 1.1 billion doses of its experimental COVID-19 vaccine to an international coalition.  

So what 

Novavax reached an agreement with Gavi, the Vaccine Alliance, to supply NVX-CoV2373, its coronavirus vaccine candidate, to the COVID-19 Vaccines Global Access (COVAX) initiative. COVAX is a global effort co-led by Gavi, the World Health Organization (WHO), and the Coalition for Epidemic Preparedness Innovations (CEPI). It's designed to facilitate the equitable distribution of vaccines around the world.

A syringe is in a drug vial that's next to other drug vials.

Shares of Novavax climbed on Friday. Image source: Getty Images.

Novavax will work with Serum Institute of India (SII) to manufacture the vaccine. "We are proud to partner with all the COVAX collaborators and Serum Institute of India to provide global public health leadership and ensure that all countries have broad access to NVX-CoV2373," Novavax CEO Stanley Erck said in a press release. "Novavax will play a critical role in the worldwide effort to provide access to safe and effective vaccines to end the pandemic."

Now what

NVX-CoV2373 has demonstrated efficacy of greater than 89% against COVID-19 in a clinical trial in the U.K., though it's believed to be less effective against new coronavirus variants. Novavax is in the process of applying for emergency use authorization (EUA) for NVX-CoV2373, and the drug is currently being evaluated in several ongoing trials.

Still, Novavax's blockbuster 1.1 billion dose supply agreement suggests that health officials believe it's only a matter of time before regulators authorize distribution of its promising COVID-19 vaccine.

"This agreement brings the COVAX Facility one step closer to its goal of supplying vaccines globally and ending the acute phase of the pandemic," Gavi CEO Dr. Seth Berkley said.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$50.70 (-2.29%) $-1.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
345%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.